Claritas HealthTech (Claritas) has announced the spin-off of its nuclear medicine division into a new entity, Claritas NucMed Technologies Ltd (Claritas NucMed), registered in the UK.

This new company will focus on the global commercialization and deployment of advanced nuclear medicine software solutions for PET and SPECT imaging.

Based in London, Claritas is known for its innovative image processing and AI diagnostic tools across various medical fields, including radiology, nuclear medicine, endoscopy, dermatology, and ophthalmology.

The company has developed advanced technologies for enhancing precision, reconstructing images, detecting lesions, and quantifying isotope uptake in PET and SPECT imaging through extensive R&D and collaboration with clinical partners.

"The creation of Claritas NucMed Technologies Ltd will enhance our ability to focus on and execute our strategic plans for delivering and deploying nuclear medicine solutions.

They dedicated R&D efforts are aimed at providing precise results that help clinicians improve patient outcomes. This new company will allow us to leverage growth opportunities in this sector."

With the increasing demand for PET-CT imaging due to rising cancer cases and other conditions, delays and long waiting times have become a concern. PET imaging is also expanding its use beyond cancer detection to include cardiac, vascular, and neurological conditions, as well as treatment monitoring.

The Claritas iPET™ technology helps reduce scan times and isotope dosage while maintaining high-quality diagnostic images. Additionally, the Claritas iPETcertum™ offers accurate and automatic lesion detection and quantification based on predefined uptake parameters.

In cardiology, Single Photon Emission Computed Tomography (SPECT) is frequently used for myocardial perfusion imaging (MPI). Claritas aims to reduce radiation exposure to patients globally with its iSPECTcardiac™ solution, which can cut scan times and/or contrast dosage by 50%.





Source: globenewswire.com

Report Abuse